HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia.

AbstractOBJECTIVES:
To evaluate the efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) compared with a combined oral contraceptive containing 1 mg norethindrone acetate and 20 mg ethinyl estradiol (OC1/20) in reducing menstrual blood loss (MBL) in women with idiopathic menorrhagia.
METHODS:
A prospective, randomized, open-label study was conducted in nine centres in Canada. Healthy women over 30 years of age suffering from idiopathic menorrhagia were treated either with LNG-IUS (n = 20) or with OC1/20 (n = 19) over 12 months. The primary endpoint was the change in MBL from baseline to 12 months. Secondary endpoints included treatment success (defined as a MBL score < 100 after 12 months), hemoglobin levels, and the menorrhagia severity score.
RESULTS:
In both treatment groups, MBL decreased significantly from baseline to 12 months (P < 0.001). For the primary endpoint, the MBL score decreased significantly more in the LNG-IUS group (median from 228 to 13, mean percent change-83%) compared to the OC1/20 group (median from 290 to 72; mean percent change-68%) (P = 0.002) after 12 months. In the LNG-IUS group, 80% of subjects had treatment success compared with 36.8 % in the OC1/20 group (P < 0.009). Both treatments increased hemoglobin concentrations significantly between baseline and 12 months. The menorrhagia severity score was consistently lower in the LNG-IUS group at all study time points and was significantly lower (P = 0.045) at six months. Both treatments were well tolerated.
CONCLUSION:
Both the LNG-IUS and the combined oral contraceptive effectively decreased menstrual blood loss in women with idiopathic menorrhagia. The overall clinical benefit was more pronounced with LNG-IUS than with OC1/20.
AuthorsJan Endrikat, Heather Shapiro, Eeva Lukkari-Lax, Michael Kunz, Werner Schmidt, Michel Fortier
JournalJournal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC (J Obstet Gynaecol Can) Vol. 31 Issue 4 Pg. 340-7 (Apr 2009) ISSN: 1701-2163 [Print] Canada
PMID19497153 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Contraceptive Agents, Female
  • Contraceptives, Oral, Synthetic
  • Estrogens
  • Hemoglobins
  • Ethinyl Estradiol
  • Levonorgestrel
  • norethindrone acetate
  • Norethindrone
Topics
  • Adult
  • Canada
  • Contraceptive Agents, Female (administration & dosage)
  • Contraceptives, Oral, Synthetic (therapeutic use)
  • Estrogens (therapeutic use)
  • Ethinyl Estradiol (therapeutic use)
  • Female
  • Hemoglobins (analysis)
  • Humans
  • Intrauterine Devices, Medicated
  • Levonorgestrel (administration & dosage)
  • Menorrhagia (drug therapy)
  • Norethindrone (analogs & derivatives, therapeutic use)
  • Prospective Studies
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: